Total
0
Shares
Medlab Clinical (ASX:MDC) - CEO, Dr Sean Hall
CEO, Dr Sean Hall
Source: Medlab Clinical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medlab’s (MDC) patented formula, NRGBiotic, has shown significant mental health outcomes for treating depression
  • 120 participants underwent the randomised, double blind, placebo-controlled study
  • Results showed participants taking both NRGBiotic and an anti-depressant had greater symptom remission over an eight-week period than those on anti-depressants alone
  • The company says its next steps include preparing results for journal publication and beginning discussions with Australian Health Authorities on potential development
  • NRGBiotic is available in Australian pharmacies, health food stores and health practitioners
  • Medlab was in the grey, last trading at 16.5 cents at 3:15 pm AEST

Medlab’s (MDC) patented formula has shown significant mental health outcomes for treating depression.

Medlab undertook a study on depression at the Queensland University of Technology, looking into the effectiveness of NRGBiotic.

NRGBiotic is a formula made up of a combination of specific probiotics and magnesium orotate, used as a treatment for major depression.

120 participants out of 1600 prospective volunteers were chosen for the randomised, double blind, placebo-controlled study.

The study results showed participants taking both NRGBiotic and an anti-depressant had greater symptom remission over an eight-week period than those on anti-depressants alone. Participants also reported a greater proportional increase in quality of life scale from baseline to eight weeks, than those on anti-depressants alone.

The study also looked into faecal analysis to see the effects on intestinal bacteria. The company says some anti-depressants upset the gastrointestinal microbiome which can further negatively influence the bioavailability of other orally ingested medicines.

Recent mental health research has suggested around 800 million people, or 10 per cent of the global population, currently live or have lived with a mental health disorder.

Despite this, research journals have demonstrated around one third of patients do not respond to prescribed anti-depressant medication.  

According to the Australian Institute of Health and Welfare, Australia spends an estimated $10.6 billion, or 8 per cent of the Federal Government Health budgets on anti-depressants — a number that’s expected to increase as a result of COVID-19.

“This study and the data collected has given Medlab keen insights to further optimise the patented NRGBiotic formulation, effectively making the formulation simpler, easier to manufacture and ultimately cheaper to the patient,” Dr Sean Hall, Medlab’s CEO said.  

“Our immediate next steps would include preparing results for journal publication and discussions with Australian Health Authorities on potential development and evidence next steps.”

NRGBiotic is currently available in Australian pharmacies, health food stores and health practitioners.

Medlab was in the grey, last trading at 16.5 cents at 3:15 pm AEST.  

MDC by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.